Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CTRC | Q99895 | 1/20 | 0.31 |
| ▸ | OGT | O15294 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.30 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513482 | 0.82 | NOS3 (0.37) | DDB1CRBNCYP19A1KMT2A | |
| SCHEMBL512802 | 0.82 | TNKS2 (0.41) | DDB1CRBNALDH1A1KMT2A | |
| SCHEMBL369351 | 0.81 | DDB1 (0.47) | DDB1CRBNCYP19A1CA2CTRC | |
| SCHEMBL513404 | 0.80 | SIRT2 (0.32) | — | |
| SCHEMBL512593 | 0.79 | DDB1 (0.43) | DDB1CRBNCYP19A1CA2 | |
| SCHEMBL1225599 | 0.77 | DDB1 (0.36) | DDB1CRBNCYP19A1CTRCOGT | |
| SCHEMBL513059 | 0.76 | NR3C1 (0.42) | DDB1CRBNCYP19A1 | |
| SCHEMBL4101191 | 0.70 | CYP19A1 (0.44) | DDB1CRBNCYP19A1CTRCTSHR | |
| SCHEMBL28826385 | 0.70 | CYP19A1 (0.44) | DDB1CRBNCYP19A1CTRCTSHR | |
| SCHEMBL367755 | 0.67 | LMNA (0.35) | DDB1CRBNCYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2459197-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| EP-2459197-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| WO-2012103297-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-02 | — | — | WO | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| WO-2011014535-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | DDB1 2948/4885CRBN 1425/4885CYP19A1 2219/4885 |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | DDB1 2948/4885CRBN 1425/4885CYP19A1 2219/4885 |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | DDB1 2948/4885CRBN 1425/4885CYP19A1 2219/4885 |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | DDB1 2948/4885CRBN 1425/4885CYP19A1 2219/4885 |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | DDB1 2948/4885CRBN 1425/4885CYP19A1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.